Recro Pharma Inc (REPH) : Stonepine Capital Management scooped up 741,930 additional shares in Recro Pharma Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 1,170,600 shares of Recro Pharma Inc which is valued at $9,306,270.Recro Pharma Inc makes up approximately 4.35% of Stonepine Capital Management’s portfolio.
Other Hedge Funds, Including , Cormorant Asset Management reduced its stake in REPH by selling 109,049 shares or 14.01% in the most recent quarter. The Hedge Fund company now holds 669,239 shares of REPH which is valued at $5,320,450. Recro Pharma Inc makes up approx 0.60% of Cormorant Asset Management’s portfolio. Tfs Capital added REPH to its portfolio by purchasing 10,436 company shares during the most recent quarter which is valued at $78,374. Recro Pharma Inc makes up approx 0.02% of Tfs Capital’s portfolio.Blackrock Investment Management boosted its stake in REPH in the latest quarter, The investment management firm added 238 additional shares and now holds a total of 1,311 shares of Recro Pharma Inc which is valued at $9,098.Blackrock Advisors boosted its stake in REPH in the latest quarter, The investment management firm added 1,315 additional shares and now holds a total of 2,418 shares of Recro Pharma Inc which is valued at $16,781.Blackrock Fund Advisors boosted its stake in REPH in the latest quarter, The investment management firm added 3,231 additional shares and now holds a total of 18,499 shares of Recro Pharma Inc which is valued at $128,383.
Recro Pharma Inc closed down -0.14 points or -1.61% at $8.57 with 1,24,127 shares getting traded on Monday. Post opening the session at $8.78, the shares hit an intraday low of $8.37 and an intraday high of $8.84 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Many Wall Street Analysts have commented on Recro Pharma Inc. Aegis Capital Initiated Recro Pharma Inc on Nov 14, 2016 to “Buy”, Price Target of the shares are set at $21.Recro Pharma Inc was Resumed by Brean Capital to “Buy” on Oct 3, 2016. Recro Pharma Inc was Initiated by ROTH Capital to “Buy” on Sep 16, 2016.
Recro Pharma Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN Dex-SL and Fadolmidine (Fado). Dex-IN is a product candidate under development for the treatment of post-operative pain and for the treatment of cancer breakthrough pain. Dex-SL is a product candidate for the treatment of chronic pain. Fado is a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies) especially of the lower extremities which can occur in diabetic patients.